Label: TRIAMCINOLONE ACETONIDE- triamcinolone acetonide cream

  • NDC Code(s): 0168-0002-15, 0168-0003-15, 0168-0003-80, 0168-0004-15, view more
    0168-0004-16, 0168-0004-80
  • Packager: E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated March 1, 2018

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx only

    Close
  • DESCRIPTION:

    Triamcinolone Acetonide Cream USP contains Triamcinolone Acetonide [Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis- (oxy)]-, (11β,16α)-], with the empirical formula C24H31FO6 and molecular weight 434.50. CAS 76-25-5.

    chemstructure

    Triamcinolone Acetonide Cream USP, 0.025% contains: 0.25 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.

    Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.

    Triamcinolone Acetonide Cream USP, 0.5% contains: 5 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.

    Close
  • CLINICAL PHARMACOLOGY:

    Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

    Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

    Close
  • INDICATIONS AND USAGE:

    Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

    Close
  • CONTRAINDICATIONS:

    Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

    Close
  • PRECAUTIONS:

    General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.

    Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-Pediatric Use). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate anti-fungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

    Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions.

    1.
    This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
    2.
    Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
    3.
    The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
    4.
    Patients should report any signs of local adverse reactions especially under occlusive dressing.
    5.
    Parents of pediatric patients should be advised not to use tight fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

    Laboratory Tests: The following tests may be helpful in evaluating the HPA axis suppression:
    Urinary free cortisol test; ACTH stimulation test.

    Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

    Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

    Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

    Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

    Close
  • ADVERSE REACTIONS:

    The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

    Close
  • OVERDOSAGE:

    Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

    Close
  • DOSAGE AND ADMINISTRATION:

    Apply to the affected area as a thin film as follows: Triamcinolone Acetonide Cream USP, 0.025% two to four times daily; Triamcinolone Acetonide Cream USP, 0.1% and 0.5% two or three times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

    Close
  • HOW SUPPLIED:

    Triamcinolone Acetonide Cream USP, 0.025%

    Triamcinolone Acetonide Cream USP, 0.1%

    15 gram tubes   NDC 0168-0003-15

    15 gram tubes   NDC 0168-0004-15

    80 gram tubes   NDC 0168-0003-80

    80 gram tubes   NDC 0168-0004-80

     

    1 Lb jars           NDC 0168-0004-16

    Triamcinolone Acetonide Cream USP, 0.5%

     

    15 gram tubes   NDC 0168-0002-15.

     

    Store at controlled room temperature 15°-30°C (59°-86°F).

    Avoid excessive heat. Protect from freezing.

    Fougera
    PHARMACEUTICALS INC.

    E. FOUGERA & CO.
    A division of Fougera Pharmaceuticals Inc.
    Melville New York 11747

    I20215G/IF20215G
    R09/11
    #227

    46165001A

    R06/15

    #65

    Close
  • PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.025% 15g CONTAINER

    NDC 0168-0003-15

    FOUGERA®
    TRIAMCINOLONE
    ACETONIDE CREAM
    USP, 0.025%

    Rx only

    FOR EXTERNAL USE ONLY.
    NOT FOR OPHTHALMIC USE.

    NET WT 15 grams

    005percentlabel.jpg
    Close
  • PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.025% 15g CARTON

    NDC 0168-0003-15

    Rx only

    FOUGERA®
    TRIAMCINOLONE
    ACETONIDE CREAM
    USP, 0.025%

    WARNING: Keep out of
    reach of children.

    FOR EXTERNAL USE ONLY.
    NOT FOR OPHTHALMIC USE.

    NET WT 15 grams

    0025percentcartonserialized
    Close
  • PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.1% 15g CONTAINER

    NDC 0168-0004-15

    FOUGERA®

    TRIAMCINOLONE
    ACETONIDE CREAM
    USP, 0.1%

    Rx only

    FOR EXTERNAL USE ONLY.
    NOT FOR OPHTHALMIC USE.

    NET WT 15 grams

    triamcream15gmtube
    Close
  • PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.1% 15g CARTON

    NDC 0168-0004-15

    Rx only

    FOUGERA®
    TRIAMCINOLONE
    ACETONIDE CREAM
    USP, 0.1%

    WARNING: Keep out of
    reach of children.

    FOR EXTERNAL USE ONLY.
    NOT FOR OPHTHALMIC USE.

    NET WT 15 grams

    01percentcartonserialized
    Close
  • PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.5% 15g CONTAINER

    NDC 0168-0002-15

    FOUGERA®

    TRIAMCINOLONE
    ACETONIDE CREAM
    USP, 0.5%

    Rx only

    FOR EXTERNAL USE ONLY.
    NOT FOR OPHTHALMIC USE
    .

    NET WT 15 grams

    05percentlabel
    Close
  • PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.5% 15g CARTON

    NDC 0168-0002-15

    Rx only

    FOUGERA®
    TRIAMCINOLONE
    ACETONIDE CREAM
    USP, 0.5%

    WARNING: Keep out of
    reach of children.

     
    FOR EXTERNAL USE ONLY.
    NOT FOR OPHTHALMIC USE.

    NET WT 15 grams

    05percentcartonserialized
    Close
  • INGREDIENTS AND APPEARANCE
    TRIAMCINOLONE ACETONIDE 
    triamcinolone acetonide cream
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0168-0003
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    triamcinolone acetonide (UNII: F446C597KA) (triamcinolone acetonide - UNII:F446C597KA) triamcinolone acetonide 0.25 mg  in 1 g
    Inactive Ingredients
    Ingredient Name Strength
    Cetyl Alcohol (UNII: 936JST6JCN)  
    Isopropyl Palmitate (UNII: 8CRQ2TH63M)  
    Sorbitol (UNII: 506T60A25R)  
    Glycerin (UNII: PDC6A3C0OX)  
    LACTIC ACID, UNSPECIFIED FORM (UNII: 33X04XA5AT)  
    Benzyl Alcohol (UNII: LKG8494WBH)  
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0168-0003-15 1 in 1 CARTON 03/09/1978
    1 15 g in 1 TUBE; Type 0: Not a Combination Product
    2 NDC:0168-0003-80 1 in 1 CARTON 03/09/1978
    2 80 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA085692 03/09/1978
    TRIAMCINOLONE ACETONIDE 
    triamcinolone acetonide cream
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0168-0004
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    triamcinolone acetonide (UNII: F446C597KA) (triamcinolone acetonide - UNII:F446C597KA) triamcinolone acetonide 1 mg  in 1 g
    Inactive Ingredients
    Ingredient Name Strength
    Cetyl Alcohol (UNII: 936JST6JCN)  
    Isopropyl Palmitate (UNII: 8CRQ2TH63M)  
    Sorbitol (UNII: 506T60A25R)  
    Glycerin (UNII: PDC6A3C0OX)  
    LACTIC ACID, UNSPECIFIED FORM (UNII: 33X04XA5AT)  
    Benzyl Alcohol (UNII: LKG8494WBH)  
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0168-0004-15 1 in 1 CARTON 03/09/1978
    1 15 g in 1 TUBE; Type 0: Not a Combination Product
    2 NDC:0168-0004-80 1 in 1 CARTON 03/09/1978
    2 80 g in 1 TUBE; Type 0: Not a Combination Product
    3 NDC:0168-0004-16 453.6 g in 1 JAR; Type 0: Not a Combination Product 03/09/1978
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA085692 03/09/1978
    TRIAMCINOLONE ACETONIDE 
    triamcinolone acetonide cream
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0168-0002
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    triamcinolone acetonide (UNII: F446C597KA) (triamcinolone acetonide - UNII:F446C597KA) triamcinolone acetonide 5 mg  in 1 g
    Inactive Ingredients
    Ingredient Name Strength
    Cetyl Alcohol (UNII: 936JST6JCN)  
    Isopropyl Palmitate (UNII: 8CRQ2TH63M)  
    Sorbitol (UNII: 506T60A25R)  
    Glycerin (UNII: PDC6A3C0OX)  
    LACTIC ACID, UNSPECIFIED FORM (UNII: 33X04XA5AT)  
    Benzyl Alcohol (UNII: LKG8494WBH)  
    Water (UNII: 059QF0KO0R)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0168-0002-15 1 in 1 CARTON 03/09/1978
    1 15 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA085692 03/09/1978
    Labeler - E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (043838424)
    Close